Ascletis Pharma Inc., commonly referred to as Ascletis, is a prominent biopharmaceutical company headquartered in China (CN). Founded in 2013, Ascletis has rapidly established itself in the biotechnology sector, focusing on the research, development, and commercialisation of innovative therapies for viral infections, liver diseases, and cancer. With a strong operational presence in major regions across Asia, Ascletis has achieved significant milestones, including the successful launch of its core products, which are distinguished by their advanced formulations and efficacy. The company is recognised for its commitment to addressing unmet medical needs, positioning itself as a leader in the competitive biopharmaceutical landscape. Ascletis continues to drive innovation, contributing to the global fight against serious health challenges.
How does Ascletis Pha B's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Ascletis Pha B's score of 20 is lower than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2021, Ascletis Pharma Inc., headquartered in China (CN), reported total carbon emissions of approximately 2,180,270 kg CO2e. This figure includes 14,630 kg CO2e from Scope 1 emissions and 2,165,640 kg CO2e from Scope 2 emissions. The company has not disclosed any Scope 3 emissions data for this year. Comparatively, in 2018, Ascletis reported total emissions of about 2,064,900 kg CO2e, with 31,400 kg CO2e from Scope 1, 2,018,300 kg CO2e from Scope 2, and 15,200 kg CO2e from Scope 3. This indicates a slight increase in total emissions from 2018 to 2021. Despite these emissions figures, Ascletis has not set any specific reduction targets or climate pledges, nor have they cascaded any targets from parent or related organizations. The absence of defined climate commitments suggests a need for further action in aligning with industry standards for carbon reduction.
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2021 | |
|---|---|---|
| Scope 1 | 31,400 | 00,000 | 
| Scope 2 | 2,018,300 | 0,000,000 | 
| Scope 3 | 15,200 | - | 
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Ascletis Pha B has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
